SlideShare uma empresa Scribd logo
1 de 16
Baixar para ler offline
A Practical Approach to
Raw Material Sourcing and
Management
Cell Culture World Congress, Munich Germany
Marlin Frechette
Director, Quality Systems and Regulatory Affairs
Irvine Scientific
Outline


Introduction



Raw Material Program
•
•

Historical Events
Program Elements
-

•

Operational Excellence
Quality Excellence
Service Excellence

Conclusion
Irvine Scientific
Introduction



40-year Cell Culture History
•



Markets Served
•
•
•



Global Coverage

Biopharmaceutical
Medical Markets
Cell Therapy

Parent Company – JX Holding (Japan)
•

25 years
Raw Material Program
Historical Events
Year

Biological Product or Vaccine

Contaminant

1940s

Yellow Fever Vaccine

Avian Leukosis Virus
Hepatitus B Virus (28,000 cases)

1950s

Polio Vaccine

SV-40 and Polio (Cutter)

1980s

Human Growth Hormone

Creutzfeldt-Jacob

1980s

Blood Derived Products, 1990s

HIV, HBV, HCV, HAV

1990s

Monoclonal Antibodies

LCMV, MVM, EHDV

2000s

Animal Derived Raw Materials

BPyV, Cache Valley

2000s

Recombinant Proteins

Vesivirus, REO-Type 2, MVM

2010

Vaccines

Porcine Circovuirus
(DNA Sequences Only)

Source: “Cell Line Testing, Raw Material Considerations, and Regulatory Guidance”, by Alan Moore, A General Presentation to Irvine Scientific,
May 6, 2011, WuXi AppTec
Raw Material Program
Elements

Best Practices

Continuous
Improvement

Custom
Requirements
Operational Excellence
Industry Best Practices
1.

Sourcing Strategy
•

Influences Supply
Chain Transparency

Suppliers
Total

Standar
Custom
d
Part #
Part #

Total

Percent
(%)

51

-

24

11

28

55%

Distributors

•

27

Manufacturer

Baseline

46

22

16

23

45%

Direct Manufacturer

52%

40%

-

-

Table 1. Manufacturers versus Distributors

> 50% raw material components from manufacturers

Directive
•

Further minimize use of distributors where possible
Operational Excellence
Industry Best Practices

•

Supply Continuity
Risk Mitigation

Baseline
•

69% dual sourced

Custom

Total

289

153

442

289

153

442

100%

Secondary

•

Standar
d

Primary

Dual Sourcing

2.

200

105

305

69%

Single Source
(%)

31%

31%

43%

31%

Raw Material
Part Number
Dual Sourcing

Table 2. Primary versus Secondary Sources

Directive
•

Percent
(%)

Continue to qualify secondary sources (riskbased)
Operational Excellence
Industry Best Practices
3.

Supply Chain
•
•

Material and Supplier Qualification - Split
Risk-based Management
Quality Excellence
Continuous Improvement
1.

Relevant Incoming QC Testing
•

•
•

2.

Material and Vendor Qualification
•

3.

Split and implement into Supply Chain

Transparency to Tertiary Level
•
•

4.

Every receipt is tested (sampling plan)
Type and use
Annual trend analysis of incoming receipts

Good communication with manufacturers and distributors
Successful ACF raw material program

Proactive analysis of new requirements
•

Case Study
Quality Excellence
Case Study
Observation:

Multiple customer inquiries for non-detectable enteric
bacterial organisms <per USP 62>.

Challenge:

Requirement not currently implemented in supply
chain.

Current Study: Establish baseline data and assess feasibility of nondetectable specification for enteric bacterial organisms
1. Raw Material Supply Chain
-

2.

Initiated discussions with vendors
Analysis of current inventory

Environmental Analysis (12-month)
-

Facilities, equipment, processess and practices
Quality Excellence
Case Study
Lots

Lots w/
Bioburde
n Counts

Lots w/
Enteric +

Lots w/
Bioburden
Counts (%)

Fermentation

101

23

0

Extraction

15

1

0

6.7%

Synthetic

73

9

0

Study Strategy

22.8 %

12.3%

Production
Method

1.

Raw Material Assessment
- Production Method
- Supplier
- Number of Lots

2.

Baseline Data
- Where to look
- Rationale for next steps

3.

Directive
- Begin routine monitoring

Table 3: Raw Material Inventory by Production Method

•

Table 4: Raw Material Inventory Bioburden – Lots Received

Raw materials and EM
Raw Material Program
Functionality

Quality Group
1.

Operational Group

Material & Vendor Qualification

1.

• Sourcing Strategy
• Dual Sourcing
• Risk-based Management
2.

Change Notification

Challenge

Supply Chain Implementation
• Sourcing Strategy
• Dual Sourcing
• Risk-based Management

2.

Change Notification

Must Talk
Must Respond

Steering
Committee

Execution
Raw Material Program
Steering Committee

Manufacturing Operations
Technical Support
Supply Chain

Quality Assurance
Quality Control
Technical Support

Sales and Marketing

Best Practices

Continuous Improvement

Seamless Integration

1. Qualification Requirements
2. Change Notification
3. Incoming QC Testing

1. Customer Requirements
2. Market Trends

1. Supply Chain
Implementation
2. Change Notification
3. Relevant Testing
Service Excellence
Seamless Integration – Custom Needs
1.

Custom Documentation Requirements
•

2.

Inventory Management
•
•

3.

Raw material documentation

Sequestered Inventory - Critical Raw Materials
Master Raw Material Lists / Requirements

Transparency to Tertiary Level
•
•

Troubleshooting
Change Notification
Raw Material Program
Conclusion
1.

Ensuring Alignment with Industry Expectations
•

2.

Practical Approach to Our Business
•

3.

Proactive versus reactive

Risk-based management

Ensuring Execution
•

Business Continuity
Acknowledgement
Jim Niemeyer
Alma Krebs
Holden Harris
Ashley Werner
Tom Fletcher
Erik Vaessen
Deb Stutz

Director of Operations
Manager, Supply Chain

Manager, Quality Assurance
Manager, Quality Control
Director, Research & Development
EU Territory Business Manager
Director, Marketing

Mais conteúdo relacionado

Mais procurados

PROCUREMENT AND SUPPLY MANAGEMENT
PROCUREMENT AND SUPPLY MANAGEMENTPROCUREMENT AND SUPPLY MANAGEMENT
PROCUREMENT AND SUPPLY MANAGEMENTAshish Hande
 
Introduction to Supply Chain Management
Introduction to Supply Chain ManagementIntroduction to Supply Chain Management
Introduction to Supply Chain Managementvishnuvsvn
 
Supply Chain Management With Brief Case Studies
Supply Chain Management With Brief Case StudiesSupply Chain Management With Brief Case Studies
Supply Chain Management With Brief Case StudiesMohit Jain
 
SUPPLIER SELECTION AND EVALUATION
SUPPLIER SELECTION AND EVALUATIONSUPPLIER SELECTION AND EVALUATION
SUPPLIER SELECTION AND EVALUATIONZamri Yahya
 
Vendor Managed Inventory
Vendor Managed InventoryVendor Managed Inventory
Vendor Managed Inventoryloganath85
 
Vendor Managed Inventory (VMI)
Vendor Managed Inventory (VMI)Vendor Managed Inventory (VMI)
Vendor Managed Inventory (VMI)Anand Subramaniam
 
Ch02 purchasing management
Ch02  purchasing managementCh02  purchasing management
Ch02 purchasing managementHemant Kr
 
Supply chain management ppt MBA
Supply chain management ppt MBA  Supply chain management ppt MBA
Supply chain management ppt MBA Babasab Patil
 
Supply chain management Understanding the Supply Chain
Supply chain management Understanding the Supply ChainSupply chain management Understanding the Supply Chain
Supply chain management Understanding the Supply ChainOsama Yousaf
 
Unit 1 Supply Chain management
Unit 1 Supply Chain managementUnit 1 Supply Chain management
Unit 1 Supply Chain managementRamachandran S
 
Supplier selection
Supplier selectionSupplier selection
Supplier selectionjoecobe
 
purchasing process
purchasing processpurchasing process
purchasing processonearbaein
 
Supply chain management
Supply chain managementSupply chain management
Supply chain managementAniket Verma
 

Mais procurados (20)

PROCUREMENT AND SUPPLY MANAGEMENT
PROCUREMENT AND SUPPLY MANAGEMENTPROCUREMENT AND SUPPLY MANAGEMENT
PROCUREMENT AND SUPPLY MANAGEMENT
 
Introduction to Supply Chain Management
Introduction to Supply Chain ManagementIntroduction to Supply Chain Management
Introduction to Supply Chain Management
 
Bullwhip effect
Bullwhip effectBullwhip effect
Bullwhip effect
 
Supply Chain Management With Brief Case Studies
Supply Chain Management With Brief Case StudiesSupply Chain Management With Brief Case Studies
Supply Chain Management With Brief Case Studies
 
Components of scm
Components of scmComponents of scm
Components of scm
 
Chopra3 ppt ch01
Chopra3 ppt ch01Chopra3 ppt ch01
Chopra3 ppt ch01
 
Supply Chain Management
Supply Chain ManagementSupply Chain Management
Supply Chain Management
 
SUPPLIER SELECTION AND EVALUATION
SUPPLIER SELECTION AND EVALUATIONSUPPLIER SELECTION AND EVALUATION
SUPPLIER SELECTION AND EVALUATION
 
Vendor Managed Inventory
Vendor Managed InventoryVendor Managed Inventory
Vendor Managed Inventory
 
Vendor Managed Inventory (VMI)
Vendor Managed Inventory (VMI)Vendor Managed Inventory (VMI)
Vendor Managed Inventory (VMI)
 
Ch02 purchasing management
Ch02  purchasing managementCh02  purchasing management
Ch02 purchasing management
 
Supply chain management ppt MBA
Supply chain management ppt MBA  Supply chain management ppt MBA
Supply chain management ppt MBA
 
Supply chain lecture
Supply chain lectureSupply chain lecture
Supply chain lecture
 
Supply chain management Understanding the Supply Chain
Supply chain management Understanding the Supply ChainSupply chain management Understanding the Supply Chain
Supply chain management Understanding the Supply Chain
 
Unit 1 Supply Chain management
Unit 1 Supply Chain managementUnit 1 Supply Chain management
Unit 1 Supply Chain management
 
Supply chain management
Supply chain managementSupply chain management
Supply chain management
 
Supplier selection
Supplier selectionSupplier selection
Supplier selection
 
Supply Chain Management and IT
Supply Chain Management and IT Supply Chain Management and IT
Supply Chain Management and IT
 
purchasing process
purchasing processpurchasing process
purchasing process
 
Supply chain management
Supply chain managementSupply chain management
Supply chain management
 

Destaque

Raw Materials Management
Raw Materials ManagementRaw Materials Management
Raw Materials Managementcori wolf
 
Effect of raw materials and production processes on dry powder media quality
Effect of raw materials and production processes on dry powder media qualityEffect of raw materials and production processes on dry powder media quality
Effect of raw materials and production processes on dry powder media qualityNational Institute of Biologics
 
Raw material management at welch’s
Raw material management at welch’sRaw material management at welch’s
Raw material management at welch’sSilmari Kim
 
Development of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsDevelopment of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsNational Institute of Biologics
 
Speeding up media design in cell culture - a novel high throughput approach f...
Speeding up media design in cell culture - a novel high throughput approach f...Speeding up media design in cell culture - a novel high throughput approach f...
Speeding up media design in cell culture - a novel high throughput approach f...National Institute of Biologics
 
NAMASTE GERMANY - Your Indian Connection to Germany
NAMASTE GERMANY - Your Indian Connection to GermanyNAMASTE GERMANY - Your Indian Connection to Germany
NAMASTE GERMANY - Your Indian Connection to Germanynamastegermany
 
Operations ppt- Mcd
Operations ppt- McdOperations ppt- Mcd
Operations ppt- Mcdastha inani
 
Germany and Their Culture- Marshall
Germany and Their Culture- MarshallGermany and Their Culture- Marshall
Germany and Their Culture- MarshallSara Marshall
 
Germany cultural group 3
Germany cultural group 3Germany cultural group 3
Germany cultural group 3Ronak Sacheti
 
Germany- Complete culture of Germany in one presentation
Germany- Complete culture of Germany in one presentationGermany- Complete culture of Germany in one presentation
Germany- Complete culture of Germany in one presentationDushyant Singh Chouhan
 
Germany- cross culture management
Germany- cross culture managementGermany- cross culture management
Germany- cross culture managementswatitakshak
 
Germany- history,culture,society,organizational structure and approach to man...
Germany- history,culture,society,organizational structure and approach to man...Germany- history,culture,society,organizational structure and approach to man...
Germany- history,culture,society,organizational structure and approach to man...syed hassan
 
Material Management and ABC analysis
Material Management and ABC analysisMaterial Management and ABC analysis
Material Management and ABC analysisDr. Sonal Mandhotra
 

Destaque (20)

Raw Materials Management
Raw Materials ManagementRaw Materials Management
Raw Materials Management
 
Effect of raw materials and production processes on dry powder media quality
Effect of raw materials and production processes on dry powder media qualityEffect of raw materials and production processes on dry powder media quality
Effect of raw materials and production processes on dry powder media quality
 
Jinja Template Engine
Jinja Template EngineJinja Template Engine
Jinja Template Engine
 
Elena security
Elena securityElena security
Elena security
 
Development of a cutting edge CHO cell culture medium
Development of a cutting edge CHO cell culture mediumDevelopment of a cutting edge CHO cell culture medium
Development of a cutting edge CHO cell culture medium
 
Raw material management at welch’s
Raw material management at welch’sRaw material management at welch’s
Raw material management at welch’s
 
Waters protein therapeutics application proctocols
Waters protein therapeutics application proctocolsWaters protein therapeutics application proctocols
Waters protein therapeutics application proctocols
 
Development of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applicationsDevelopment of novel chemically defined media for CHO cell applications
Development of novel chemically defined media for CHO cell applications
 
Evaluation of antibody drugs quality safety
Evaluation of antibody drugs quality safetyEvaluation of antibody drugs quality safety
Evaluation of antibody drugs quality safety
 
Speeding up media design in cell culture - a novel high throughput approach f...
Speeding up media design in cell culture - a novel high throughput approach f...Speeding up media design in cell culture - a novel high throughput approach f...
Speeding up media design in cell culture - a novel high throughput approach f...
 
NAMASTE GERMANY - Your Indian Connection to Germany
NAMASTE GERMANY - Your Indian Connection to GermanyNAMASTE GERMANY - Your Indian Connection to Germany
NAMASTE GERMANY - Your Indian Connection to Germany
 
Operations ppt- Mcd
Operations ppt- McdOperations ppt- Mcd
Operations ppt- Mcd
 
Germany and Their Culture- Marshall
Germany and Their Culture- MarshallGermany and Their Culture- Marshall
Germany and Their Culture- Marshall
 
Germany cultural group 3
Germany cultural group 3Germany cultural group 3
Germany cultural group 3
 
Germany- Complete culture of Germany in one presentation
Germany- Complete culture of Germany in one presentationGermany- Complete culture of Germany in one presentation
Germany- Complete culture of Germany in one presentation
 
Germany- cross culture management
Germany- cross culture managementGermany- cross culture management
Germany- cross culture management
 
Usp biotherapeutics - biological medicines
Usp  biotherapeutics - biological medicinesUsp  biotherapeutics - biological medicines
Usp biotherapeutics - biological medicines
 
Germany- history,culture,society,organizational structure and approach to man...
Germany- history,culture,society,organizational structure and approach to man...Germany- history,culture,society,organizational structure and approach to man...
Germany- history,culture,society,organizational structure and approach to man...
 
Types of fabrics
Types of fabricsTypes of fabrics
Types of fabrics
 
Material Management and ABC analysis
Material Management and ABC analysisMaterial Management and ABC analysis
Material Management and ABC analysis
 

Semelhante a A practical approach to raw material sourcing and management in cell culture

Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Merck Life Sciences
 
How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?MilliporeSigma
 
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
Rapid Methodologies for Biosafety Testing of Biologic TherapeuticsRapid Methodologies for Biosafety Testing of Biologic Therapeutics
Rapid Methodologies for Biosafety Testing of Biologic TherapeuticsMerck Life Sciences
 
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
Rapid Methodologies for Biosafety Testing of Biologic TherapeuticsRapid Methodologies for Biosafety Testing of Biologic Therapeutics
Rapid Methodologies for Biosafety Testing of Biologic TherapeuticsMilliporeSigma
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyMerck Life Sciences
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyMilliporeSigma
 
food_hygiene_haccp.ppt
food_hygiene_haccp.pptfood_hygiene_haccp.ppt
food_hygiene_haccp.pptAsimP2
 
Update on animal health component 1.1
Update on animal health component 1.1Update on animal health component 1.1
Update on animal health component 1.1ILRI
 
Quality Assurance Qual Indicators.ppt
Quality Assurance Qual Indicators.pptQuality Assurance Qual Indicators.ppt
Quality Assurance Qual Indicators.pptSUNILDhatwalia1
 
220315 qassurance presentation_for_haccp_team_ training_cve
220315 qassurance presentation_for_haccp_team_ training_cve220315 qassurance presentation_for_haccp_team_ training_cve
220315 qassurance presentation_for_haccp_team_ training_cveGeorgeMiedema
 
GLP-CONCEPT.ppt
GLP-CONCEPT.pptGLP-CONCEPT.ppt
GLP-CONCEPT.pptiamviksin
 
Erica Canzler - Advances and Lessons Learned in Decontamination
Erica Canzler - Advances and Lessons Learned in DecontaminationErica Canzler - Advances and Lessons Learned in Decontamination
Erica Canzler - Advances and Lessons Learned in DecontaminationMatthew Kirkby
 
New HACCP Regulations - Plan Now!
New HACCP Regulations - Plan Now!New HACCP Regulations - Plan Now!
New HACCP Regulations - Plan Now!Alchemy Systems
 
WVC 2013 Merck Millipore Frank Appel Ensuring Critical Vaccine Supply
WVC 2013 Merck Millipore  Frank Appel Ensuring Critical Vaccine SupplyWVC 2013 Merck Millipore  Frank Appel Ensuring Critical Vaccine Supply
WVC 2013 Merck Millipore Frank Appel Ensuring Critical Vaccine SupplyFrank Appel
 
IPAR-Rwanda's Annual Research Conference at Umubano Hotel from 28-29 January ...
IPAR-Rwanda's Annual Research Conference at Umubano Hotel from 28-29 January ...IPAR-Rwanda's Annual Research Conference at Umubano Hotel from 28-29 January ...
IPAR-Rwanda's Annual Research Conference at Umubano Hotel from 28-29 January ...Bosco Hitimana
 

Semelhante a A practical approach to raw material sourcing and management in cell culture (20)

Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?Viral safety of biologics: What's changing with the ICH Q5A revision?
Viral safety of biologics: What's changing with the ICH Q5A revision?
 
How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?How does the ICH Q5A revision impact viral safety strategies for biologics?
How does the ICH Q5A revision impact viral safety strategies for biologics?
 
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
Rapid Methodologies for Biosafety Testing of Biologic TherapeuticsRapid Methodologies for Biosafety Testing of Biologic Therapeutics
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
 
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
Rapid Methodologies for Biosafety Testing of Biologic TherapeuticsRapid Methodologies for Biosafety Testing of Biologic Therapeutics
Rapid Methodologies for Biosafety Testing of Biologic Therapeutics
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene Therapy
 
Latest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene TherapyLatest Updates in Biosafety Testing for Gene Therapy
Latest Updates in Biosafety Testing for Gene Therapy
 
haccpvideo.ppt
haccpvideo.ppthaccpvideo.ppt
haccpvideo.ppt
 
food_hygiene_haccp.ppt
food_hygiene_haccp.pptfood_hygiene_haccp.ppt
food_hygiene_haccp.ppt
 
Update on animal health component 1.1
Update on animal health component 1.1Update on animal health component 1.1
Update on animal health component 1.1
 
Quality Assurance Qual Indicators.ppt
Quality Assurance Qual Indicators.pptQuality Assurance Qual Indicators.ppt
Quality Assurance Qual Indicators.ppt
 
220315 qassurance presentation_for_haccp_team_ training_cve
220315 qassurance presentation_for_haccp_team_ training_cve220315 qassurance presentation_for_haccp_team_ training_cve
220315 qassurance presentation_for_haccp_team_ training_cve
 
Quality control
Quality controlQuality control
Quality control
 
GLP-CONCEPT.ppt
GLP-CONCEPT.pptGLP-CONCEPT.ppt
GLP-CONCEPT.ppt
 
Erica Canzler - Advances and Lessons Learned in Decontamination
Erica Canzler - Advances and Lessons Learned in DecontaminationErica Canzler - Advances and Lessons Learned in Decontamination
Erica Canzler - Advances and Lessons Learned in Decontamination
 
New HACCP Regulations - Plan Now!
New HACCP Regulations - Plan Now!New HACCP Regulations - Plan Now!
New HACCP Regulations - Plan Now!
 
RESUME BP OCT16
RESUME BP OCT16RESUME BP OCT16
RESUME BP OCT16
 
WVC 2013 Merck Millipore Frank Appel Ensuring Critical Vaccine Supply
WVC 2013 Merck Millipore  Frank Appel Ensuring Critical Vaccine SupplyWVC 2013 Merck Millipore  Frank Appel Ensuring Critical Vaccine Supply
WVC 2013 Merck Millipore Frank Appel Ensuring Critical Vaccine Supply
 
AA
AAAA
AA
 
Cosmetic microbiology
Cosmetic microbiologyCosmetic microbiology
Cosmetic microbiology
 
IPAR-Rwanda's Annual Research Conference at Umubano Hotel from 28-29 January ...
IPAR-Rwanda's Annual Research Conference at Umubano Hotel from 28-29 January ...IPAR-Rwanda's Annual Research Conference at Umubano Hotel from 28-29 January ...
IPAR-Rwanda's Annual Research Conference at Umubano Hotel from 28-29 January ...
 

Mais de National Institute of Biologics

Defining your-target-product-profile in-vitro-diagnostic-products
Defining your-target-product-profile in-vitro-diagnostic-productsDefining your-target-product-profile in-vitro-diagnostic-products
Defining your-target-product-profile in-vitro-diagnostic-productsNational Institute of Biologics
 
Accelerating development and approval of targeted cancer therapies
Accelerating development and approval of targeted cancer therapiesAccelerating development and approval of targeted cancer therapies
Accelerating development and approval of targeted cancer therapiesNational Institute of Biologics
 
Canonical structures for the hypervariable regions of immunoglobulins
Canonical structures for the hypervariable regions of immunoglobulinsCanonical structures for the hypervariable regions of immunoglobulins
Canonical structures for the hypervariable regions of immunoglobulinsNational Institute of Biologics
 
Development trends for human monoclonal antibody therapeutics
Development trends for human monoclonal antibody therapeuticsDevelopment trends for human monoclonal antibody therapeutics
Development trends for human monoclonal antibody therapeuticsNational Institute of Biologics
 
Therapeutic fc fusion proteins and peptides as successful alternatives to ant...
Therapeutic fc fusion proteins and peptides as successful alternatives to ant...Therapeutic fc fusion proteins and peptides as successful alternatives to ant...
Therapeutic fc fusion proteins and peptides as successful alternatives to ant...National Institute of Biologics
 
Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...
Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...
Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...National Institute of Biologics
 
Therapeutic antibodies for autoimmunity and inflammation
Therapeutic antibodies for autoimmunity and inflammationTherapeutic antibodies for autoimmunity and inflammation
Therapeutic antibodies for autoimmunity and inflammationNational Institute of Biologics
 
Introduction to current and future protein therapeutics - a protein engineeri...
Introduction to current and future protein therapeutics - a protein engineeri...Introduction to current and future protein therapeutics - a protein engineeri...
Introduction to current and future protein therapeutics - a protein engineeri...National Institute of Biologics
 
Pharmaceutical monoclonal antibodies production - guidelines to cell engine...
Pharmaceutical monoclonal antibodies   production - guidelines to cell engine...Pharmaceutical monoclonal antibodies   production - guidelines to cell engine...
Pharmaceutical monoclonal antibodies production - guidelines to cell engine...National Institute of Biologics
 
Intended use of reference products & who international standards or reference...
Intended use of reference products & who international standards or reference...Intended use of reference products & who international standards or reference...
Intended use of reference products & who international standards or reference...National Institute of Biologics
 
Evaluation of similar biotherapeutic products (SBP's) scientific principles ...
Evaluation of similar biotherapeutic products (SBP's)   scientific principles ...Evaluation of similar biotherapeutic products (SBP's)   scientific principles ...
Evaluation of similar biotherapeutic products (SBP's) scientific principles ...National Institute of Biologics
 
Biologicals and biosimilars a review of the science and its implications
Biologicals and biosimilars   a review of the science and its implicationsBiologicals and biosimilars   a review of the science and its implications
Biologicals and biosimilars a review of the science and its implicationsNational Institute of Biologics
 

Mais de National Institute of Biologics (20)

Potential aggregation prone regions in biotherapeutics
Potential aggregation prone regions in biotherapeuticsPotential aggregation prone regions in biotherapeutics
Potential aggregation prone regions in biotherapeutics
 
How the biologics landscape is evolving
How the biologics landscape is evolvingHow the biologics landscape is evolving
How the biologics landscape is evolving
 
Approved m abs_feb_2015
Approved m abs_feb_2015Approved m abs_feb_2015
Approved m abs_feb_2015
 
Translating next generation sequencing to practice
Translating next generation sequencing to practiceTranslating next generation sequencing to practice
Translating next generation sequencing to practice
 
From biomarkers to diagnostics –the road to success
From biomarkers to diagnostics –the road to successFrom biomarkers to diagnostics –the road to success
From biomarkers to diagnostics –the road to success
 
Defining your-target-product-profile in-vitro-diagnostic-products
Defining your-target-product-profile in-vitro-diagnostic-productsDefining your-target-product-profile in-vitro-diagnostic-products
Defining your-target-product-profile in-vitro-diagnostic-products
 
Accelerating development and approval of targeted cancer therapies
Accelerating development and approval of targeted cancer therapiesAccelerating development and approval of targeted cancer therapies
Accelerating development and approval of targeted cancer therapies
 
Canonical structures for the hypervariable regions of immunoglobulins
Canonical structures for the hypervariable regions of immunoglobulinsCanonical structures for the hypervariable regions of immunoglobulins
Canonical structures for the hypervariable regions of immunoglobulins
 
Canonical correlation
Canonical correlationCanonical correlation
Canonical correlation
 
Development trends for human monoclonal antibody therapeutics
Development trends for human monoclonal antibody therapeuticsDevelopment trends for human monoclonal antibody therapeutics
Development trends for human monoclonal antibody therapeutics
 
Therapeutic fc fusion proteins and peptides as successful alternatives to ant...
Therapeutic fc fusion proteins and peptides as successful alternatives to ant...Therapeutic fc fusion proteins and peptides as successful alternatives to ant...
Therapeutic fc fusion proteins and peptides as successful alternatives to ant...
 
Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...
Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...
Fc fusion proteins and fc rn - structural insights for longer-lasting and mor...
 
Therapeutic antibodies for autoimmunity and inflammation
Therapeutic antibodies for autoimmunity and inflammationTherapeutic antibodies for autoimmunity and inflammation
Therapeutic antibodies for autoimmunity and inflammation
 
Introduction to current and future protein therapeutics - a protein engineeri...
Introduction to current and future protein therapeutics - a protein engineeri...Introduction to current and future protein therapeutics - a protein engineeri...
Introduction to current and future protein therapeutics - a protein engineeri...
 
Pharmaceutical monoclonal antibodies production - guidelines to cell engine...
Pharmaceutical monoclonal antibodies   production - guidelines to cell engine...Pharmaceutical monoclonal antibodies   production - guidelines to cell engine...
Pharmaceutical monoclonal antibodies production - guidelines to cell engine...
 
Intended use of reference products & who international standards or reference...
Intended use of reference products & who international standards or reference...Intended use of reference products & who international standards or reference...
Intended use of reference products & who international standards or reference...
 
How dissimilarly similar are biosimilars
How dissimilarly similar are biosimilarsHow dissimilarly similar are biosimilars
How dissimilarly similar are biosimilars
 
Evaluation of similar biotherapeutic products (SBP's) scientific principles ...
Evaluation of similar biotherapeutic products (SBP's)   scientific principles ...Evaluation of similar biotherapeutic products (SBP's)   scientific principles ...
Evaluation of similar biotherapeutic products (SBP's) scientific principles ...
 
Biosimilars - global scenario and challenges
Biosimilars  - global scenario and challengesBiosimilars  - global scenario and challenges
Biosimilars - global scenario and challenges
 
Biologicals and biosimilars a review of the science and its implications
Biologicals and biosimilars   a review of the science and its implicationsBiologicals and biosimilars   a review of the science and its implications
Biologicals and biosimilars a review of the science and its implications
 

Último

Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxkomalt2001
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyZurück zum Ursprung
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaSujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024EwoutSteyerberg1
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...Shubhanshu Gaurav
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyMedicoseAcademics
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project reportNARMADAPETROLEUMGAS
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentsaileshpanda05
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfDolisha Warbi
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu Medical University
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Peter Embi
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Vaikunthan Rajaratnam
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondSujoy Dasgupta
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionkrishnareddy157915
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptxWINCY THIRUMURUGAN
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE Mamatha Lakka
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfMedicoseAcademics
 

Último (20)

Basic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptxBasic structure of hair and hair growth cycle.pptx
Basic structure of hair and hair growth cycle.pptx
 
How to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturallyHow to cure cirrhosis and chronic hepatitis naturally
How to cure cirrhosis and chronic hepatitis naturally
 
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy DasguptaMale Infertility Panel Discussion by Dr Sujoy Dasgupta
Male Infertility Panel Discussion by Dr Sujoy Dasgupta
 
Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024Trustworthiness of AI based predictions Aachen 2024
Trustworthiness of AI based predictions Aachen 2024
 
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
FDMA FLAP - The first dorsal metacarpal artery (FDMA) flap is used mainly for...
 
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...Biologic therapy ice breaking in rheumatology, Case based approach with appli...
Biologic therapy ice breaking in rheumatology, Case based approach with appli...
 
Female Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before PregnancyFemale Reproductive Physiology Before Pregnancy
Female Reproductive Physiology Before Pregnancy
 
blood bank management system project report
blood bank management system project reportblood bank management system project report
blood bank management system project report
 
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
Immune labs basics part 1 acute phase reactants ESR, CRP Ahmed Yehia Ismaeel,...
 
CPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing studentCPR.nursingoutlook.pdf , Bsc nursing student
CPR.nursingoutlook.pdf , Bsc nursing student
 
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
How to master Steroid (glucocorticoids) prescription, different scenarios, ca...
 
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdfCONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
CONNECTIVE TISSUE (ANATOMY AND PHYSIOLOGY).pdf
 
historyofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusanguhistoryofpsychiatryinindia. Senthil Thirusangu
historyofpsychiatryinindia. Senthil Thirusangu
 
Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024Clinical Research Informatics Year-in-Review 2024
Clinical Research Informatics Year-in-Review 2024
 
Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.Generative AI in Health Care a scoping review and a persoanl experience.
Generative AI in Health Care a scoping review and a persoanl experience.
 
Male Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and BeyondMale Infertility, Antioxidants and Beyond
Male Infertility, Antioxidants and Beyond
 
EXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung functionEXERCISE PERFORMANCE.pptx, Lung function
EXERCISE PERFORMANCE.pptx, Lung function
 
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptxANATOMICAL FAETURES OF BONES  FOR NURSING STUDENTS .pptx
ANATOMICAL FAETURES OF BONES FOR NURSING STUDENTS .pptx
 
BENIGN BREAST DISEASE
BENIGN BREAST DISEASE BENIGN BREAST DISEASE
BENIGN BREAST DISEASE
 
Red Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdfRed Blood Cells_anemia & polycythemia.pdf
Red Blood Cells_anemia & polycythemia.pdf
 

A practical approach to raw material sourcing and management in cell culture

  • 1. A Practical Approach to Raw Material Sourcing and Management Cell Culture World Congress, Munich Germany Marlin Frechette Director, Quality Systems and Regulatory Affairs Irvine Scientific
  • 2. Outline  Introduction  Raw Material Program • • Historical Events Program Elements - • Operational Excellence Quality Excellence Service Excellence Conclusion
  • 3. Irvine Scientific Introduction  40-year Cell Culture History •  Markets Served • • •  Global Coverage Biopharmaceutical Medical Markets Cell Therapy Parent Company – JX Holding (Japan) • 25 years
  • 4. Raw Material Program Historical Events Year Biological Product or Vaccine Contaminant 1940s Yellow Fever Vaccine Avian Leukosis Virus Hepatitus B Virus (28,000 cases) 1950s Polio Vaccine SV-40 and Polio (Cutter) 1980s Human Growth Hormone Creutzfeldt-Jacob 1980s Blood Derived Products, 1990s HIV, HBV, HCV, HAV 1990s Monoclonal Antibodies LCMV, MVM, EHDV 2000s Animal Derived Raw Materials BPyV, Cache Valley 2000s Recombinant Proteins Vesivirus, REO-Type 2, MVM 2010 Vaccines Porcine Circovuirus (DNA Sequences Only) Source: “Cell Line Testing, Raw Material Considerations, and Regulatory Guidance”, by Alan Moore, A General Presentation to Irvine Scientific, May 6, 2011, WuXi AppTec
  • 5. Raw Material Program Elements Best Practices Continuous Improvement Custom Requirements
  • 6. Operational Excellence Industry Best Practices 1. Sourcing Strategy • Influences Supply Chain Transparency Suppliers Total Standar Custom d Part # Part # Total Percent (%) 51 - 24 11 28 55% Distributors • 27 Manufacturer Baseline 46 22 16 23 45% Direct Manufacturer 52% 40% - - Table 1. Manufacturers versus Distributors > 50% raw material components from manufacturers Directive • Further minimize use of distributors where possible
  • 7. Operational Excellence Industry Best Practices • Supply Continuity Risk Mitigation Baseline • 69% dual sourced Custom Total 289 153 442 289 153 442 100% Secondary • Standar d Primary Dual Sourcing 2. 200 105 305 69% Single Source (%) 31% 31% 43% 31% Raw Material Part Number Dual Sourcing Table 2. Primary versus Secondary Sources Directive • Percent (%) Continue to qualify secondary sources (riskbased)
  • 8. Operational Excellence Industry Best Practices 3. Supply Chain • • Material and Supplier Qualification - Split Risk-based Management
  • 9. Quality Excellence Continuous Improvement 1. Relevant Incoming QC Testing • • • 2. Material and Vendor Qualification • 3. Split and implement into Supply Chain Transparency to Tertiary Level • • 4. Every receipt is tested (sampling plan) Type and use Annual trend analysis of incoming receipts Good communication with manufacturers and distributors Successful ACF raw material program Proactive analysis of new requirements • Case Study
  • 10. Quality Excellence Case Study Observation: Multiple customer inquiries for non-detectable enteric bacterial organisms <per USP 62>. Challenge: Requirement not currently implemented in supply chain. Current Study: Establish baseline data and assess feasibility of nondetectable specification for enteric bacterial organisms 1. Raw Material Supply Chain - 2. Initiated discussions with vendors Analysis of current inventory Environmental Analysis (12-month) - Facilities, equipment, processess and practices
  • 11. Quality Excellence Case Study Lots Lots w/ Bioburde n Counts Lots w/ Enteric + Lots w/ Bioburden Counts (%) Fermentation 101 23 0 Extraction 15 1 0 6.7% Synthetic 73 9 0 Study Strategy 22.8 % 12.3% Production Method 1. Raw Material Assessment - Production Method - Supplier - Number of Lots 2. Baseline Data - Where to look - Rationale for next steps 3. Directive - Begin routine monitoring Table 3: Raw Material Inventory by Production Method • Table 4: Raw Material Inventory Bioburden – Lots Received Raw materials and EM
  • 12. Raw Material Program Functionality Quality Group 1. Operational Group Material & Vendor Qualification 1. • Sourcing Strategy • Dual Sourcing • Risk-based Management 2. Change Notification Challenge Supply Chain Implementation • Sourcing Strategy • Dual Sourcing • Risk-based Management 2. Change Notification Must Talk Must Respond Steering Committee Execution
  • 13. Raw Material Program Steering Committee Manufacturing Operations Technical Support Supply Chain Quality Assurance Quality Control Technical Support Sales and Marketing Best Practices Continuous Improvement Seamless Integration 1. Qualification Requirements 2. Change Notification 3. Incoming QC Testing 1. Customer Requirements 2. Market Trends 1. Supply Chain Implementation 2. Change Notification 3. Relevant Testing
  • 14. Service Excellence Seamless Integration – Custom Needs 1. Custom Documentation Requirements • 2. Inventory Management • • 3. Raw material documentation Sequestered Inventory - Critical Raw Materials Master Raw Material Lists / Requirements Transparency to Tertiary Level • • Troubleshooting Change Notification
  • 15. Raw Material Program Conclusion 1. Ensuring Alignment with Industry Expectations • 2. Practical Approach to Our Business • 3. Proactive versus reactive Risk-based management Ensuring Execution • Business Continuity
  • 16. Acknowledgement Jim Niemeyer Alma Krebs Holden Harris Ashley Werner Tom Fletcher Erik Vaessen Deb Stutz Director of Operations Manager, Supply Chain Manager, Quality Assurance Manager, Quality Control Director, Research & Development EU Territory Business Manager Director, Marketing

Notas do Editor

  1. Thank you all for being here today, I am very excited to be here, to present our raw material sourcing and management program. As Quality Director, I am very passionate about this subject and I know from experience that many in the cell culture industry share the same passion with me. We deeply believe that raw material and it’s management play a very critical role at the reducing risk during the manufacturing of biopharmaceuticals.
  2. Many of you are familiar with Irvine Scientific and some might not be, so I will present a brief introduction of our company and an overview of our recently formalized raw material program, historical events, program elements, which includes quality, operational and Service and I will conclude with an explanation as to why we decided to formalized our raw material program.
  3. IS is a cell culture media company. Established in 1970 originally as a serum supplierwithin a few years expanded the product offering to include cell culture productsToday, we are cell culture media supplier and that is what we do, it is the sole business of our organizationAs a media company we serve three markets the Biopharmaceutical for Industrial Cell Culture applications, the medical market with ART products, and the cell therapy with specialty media. Our parent company JX Holding with headquarters in Japan.
  4. Many of us are familiar with the historical events that have taken place with contaminated products by an unexpected contaminants.We know that the evolution with the raw material requirements have been driven by industry impacting events. We recognized the importance to address risk whether actual or potentialWe have gain perspective and understanding basically not only what can go wrong, but learning what can we do to prevent it. Those responsible for Cell Culture manufacturing process are concerned with the risk of process contamination and we as media supply partner play a role at minimizing the risk.
  5. I was talking about raw materials controls and concerns over 10 years ago… Issues associated with raw materials and the supply chain is a topic here to stay. Last year we decided to take a more integrated approach to managing current and potential challenges with raw material supply (both for us and our customers) by creating an internal program called ‘The Raw Material Program. While we have always had the operational and quality elements as they relate to raw material management, our program now takes a more integrated approach. I’ll now walk you through each of the three major components of our program which incorporates best practices, a continuous improvement approach, and integration of custom requirements.
  6. Operational: I am going to talk about three top priority. The first priority we identified, was sourcing strategy, which impacts our ability to manage toward this transparency and is therefore our first priority within the program. The first thing we did was assess how the status of manufacturers vs. distributors with our raw materials We manage our raw materials in two categories – Irvine Scientific’s general inventory and inventory dedicated to specific customer requirements. This table provides an example of our approach, which was to have a clear understanding of what we had in terms of direct manufacturers and distributors. Knowing where we were starting, our internal directive is to further our use of direct manufacturers where possible.
  7. The second operationalstrategy:Dual sourcing, ensures supply continuity and is a preventive measure to avoid production delays. It was very important to understand where we were at in terms of single and secondary sources, a analysis was completed to understand our base line.
  8. The supply chain is the third critical priority in our program it was something in existing and for this part we are very strong, this operational functionality if is very robust5 key elements: Supplier qualification, material qualification, Change notification, purchasing controls and inventory controls. While they currently exists and operates in a robust manner, the objective of our program is to continue to focused in a risk based management.
  9. Relevant Incoming QC: testing by type and how the raw material is used, it’s impact in the final product, Industry accepted sampling plan ANSI.Z1.4 Normal of ISO 2859Material and vendor qualification:Transparency to Tertiary LevelGood Communication with manufactures and distributors That is what allowed us to implement a succesfull ACF raw material program, part of the program is to certified all the components have to be certified by the suppliers free of animal component to the tertiary level of exposure. TL= Primary animal tissue, secondary animal enzyme in the mfg process, tertiary exposure, the enzyme is not animal derived, but there was exposure during the production of the enzyme As a custom media partner we have a very unique advantage, we received many request from our customers and with this have the opportunity to learn new requirements. In a moment I will present a case study that was generated from a custom request. At times some industry requirements are real and sometimes might not be feasible or value added, but this is our responsibility to know.
  10. Inquiries enteric free media. An assessment had to be done, since this type of testing was not normally performed on all raw materials and final products. Our challenge was in the supply chain, as we investigated our suppliers informed us that they were not testing for this specific organism. Steps were taken to determine current conditions of raws, environment, associated equipment and practices. Once we found where we were at we can make decisions on how to move forward.
  11. Raw materials were chosen based on their prevalence in ICC formulations. These were tested for standard bioburden in addition to enteric bioburden.Studies showed some materials (fermentation) were more susceptible to bioburden in general, Enteric was not seen in the raw materials at all.What we learned is that some were more susceptible and that we should continue to monitor these more. The message is that for this customer their formulations we were able to implement Enteric free specification.TSAT= Trypticase Soy AgarSAB= Sabouroud Dextrose AgarVR= Violet red Bile Glucose Agar
  12. RM functionality:Quality created a directive for the operational group, in terms of material and vendor qualification. (Sourcing strategy, dual sourcing,….) operational group must execute and integrate the direction into the supply chain.While the functionality was always there, the challenge was that the priorities were not always in alignment, therefore the execution is not always in alignment. How did we solved the challenge? We included an additional piece to the functionality technical and sales and marketing and created an internal steering committee to improve execution.
  13. The steering committee includes operations, quality, technical, sales and marketing groups. This committee is going to assess the needs of our business, will determine priorities and strategies and ensures alignment with industry requirements and a very critical piece a seamless integration of our customer requests.
  14. Here are some examples seamless integration of our customer requirement for custom products.
  15. At the end of our day, we want our business to be in alignment with industry expectations. Want to take a practical approach to our business utilizing risk based and value added strategies. Ultimately our goal is to ensure business continuity and no interruption of our supply from our suppliers to our customers.
  16. I would like to Acknowledge the steering committee team for collaborating tirelessly to the success of our Raw material program